Germany's MWG Biotech has said it will slash nearly two thirds of
its workforce in a further effort to reduce costs, prompting
speculation about the long-term future of the company in its
present state.
Genomics specialist MWG Biotech has decided to pull out of
microarrays and laboratory automation and focus on its core areas
of making nucleic acids and oligonucleotides and DNA sequencing.
Germany's MWG Biotech has launched its own line of small
interfering RNA (siRNA) reagents, siMAX, encroaching into territory
dominated by the likes of Qiagen, Dharmacon, Ambion, Proligo and
Invitrogen.
MWG links up with Quanta Biotech to launch a new offensive on the
market for thermal cyclers, often described as a "must-have"
laboratory tool. The deal also marks MWG's first entry into
real-time thermal cyclers.